The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Can frontline treatment of DLBCL be improved by combining novel agents with R-CHOP?
Featured:
Andrew DaviesDuring the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub spoke with Andrew Davies, University of Southampton, Southampton, UK. We asked, Can frontline treatment of DLBCL be improved by combining novel agents with R-CHOP?
Can frontline treatment of DLBCL be improved by combining novel agents with R-CHOP?
Davies begins by explaining how frontline therapies can be stratified according to biological risk factors and reviewing data on the potential benefit of augmented therapy in high-risk patients. Davies then discusses the impact of adding bortezomib to R-CHOP on overall and progression-free survival in patients with certain molecular subgroups of DLBCL. Finally, he reviews other novel therapies showing promise in combination with R-CHOP, including acalabrutinib and glofitamab.